CMT's Medical Evidence Library

GUIDANCE DOCUMENT (FDA) Investigational COVID-19 Convalescent Plasma

SEPT 24-26, 2020 in ATLANTA, GA USA — LEARN MORE … Register …

GUIDANCE DOCUMENT | April 2020 | Content current as of:

Investigational COVID-19 Convalescent Plasma Guidance for Industry

Docket Number: FDA-2020-D-1137
Issued by: Office of Medical Products and Tobacco, Center for Biologics Evaluation and Research

The Food and Drug Administration (FDA or Agency) plays a critical role in protecting the United States (U.S.) from threats including emerging infectious diseases, such as the Coronavirus Disease 2019 (COVID-19) pandemic.  FDA is committed to providing timely guidance to support response efforts to this pandemic.

FDA is issuing this guidance to provide recommendations to health care providers and investigators on the administration and study of investigational convalescent plasma collected from individuals who have recovered from COVID-19 (COVID-19 convalescent plasma) during the public health emergency.  The guidance also provides recommendations to blood establishments on the collection of COVID-19 convalescent plasma.

Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document’s docket number: FDA-2020-D-1137.


Office of Communication, Outreach and Development (OCOD)
Center for Biologics Evaluation and Research
Food and Drug Administration
10903 New Hampshire Ave WO71-3128
Silver Spring, MD 20993-0002